黑钻治疗公司将于9月23日发布BDTX-1535在复发性EGFRmNSCLC的第二阶段试验结果. Black Diamond Therapeutics to present Phase 2 trial results for BDTX-1535 in recurrent EGFRm NSCLC on Sept 23.

黑钻疗法公司将于9月23日上午8点主持网络广播. Black Diamond Therapeutics will host a webcast on September 23 at 8:00 a.m. 预计将公布BDTX-1535的初步第二期临床试验结果,该试验针对复发性EGFRm NSCLC. ET to reveal initial Phase 2 clinical trial results for BDTX-1535, targeting recurrent EGFRm NSCLC. 该活动将在他们的网站上公布,然后重播。 The event will be available on their website, with a replay afterwards. 该公司专注于癌症突变的治疗方法,并正在推进两个项目:BDTX-1535用于NSCLC和质母细胞瘤,以及BDTX-4933用于具有特定遗传变化的固体瘤. The company focuses on therapies for cancer mutations and is advancing two programs: BDTX-1535 for NSCLC and glioblastoma, and BDTX-4933 for solid tumors with specific genetic alterations.